Option chain shows key data for Okamura's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Okamura.

Okamura (OTC:OKAMF) Stock, Option Chain

Okamura Corp is a Japanese manufacturer that operates through three segments. The office furniture segment provides office seating, desks, storage, filing supplies, room furniture, and fixtures. The store displays segment comprises products including display fixtures for food and stores, checkout facilities, and showcases. The material handling systems and others segment consists of automated warehouse, conveyor systems, sorting systems, shelves, and equipment for plants and warehouses. Combined, the office furniture and store displays segments contribute the majority of group sales. Okamura's products are manufactured both in Japan and overseas and are delivered across the world by its distribution network.

Okamura Corp

WIIM

MRUS

Merus shares are trading lower. The company announced a  research collaboration and license agreement with Biohaven to co-develop three novel bispecific antibody drug conjugates.

Citigroup analyst Andrew Kaplowitz maintains Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) with a Neutral and lowers the price target from $85 to $84.

News

Price Target

Analyst Ratings

Citigroup Maintains Neutral on Johnson Controls Intl, Lowers Price Target to $84

Citigroup analyst Vladimir Bystricky maintains ITT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITT#NYSE">ITT</a>) with a Buy and lowers the price target from $183 to $181.

Citigroup Maintains Buy on ITT, Lowers Price Target to $181

IRTC

iRhythm Technologies shares are trading lower. The company reported preliminary Q4 financial results.

Needham analyst John Todaro maintained Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and raised the <a target="_blank" href="https://www.benzinga.com/quote/BTDR/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$14&nbsp;to&nbsp;$22</a>.
Todaro raised his price target and 2025 estimates after updating his expectations for machine manufacturing sales. Additionally, the analyst increased his valuation due to his growing confidence in Bitdeer&#8217;s high-performance computing opportunities.
He modeled $175 million in machine sales, which includes the previously announced 29,000 unit sale and his estimates for the fourth quarter of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/42897081/nvidia-and-ai-chip-stocks-brace-for-impact-as-biden-administration-considers-new-china-export-ban-report" rel="noreferrer noopener">Nvidia and AI Chip Stocks Brace for Impact as Biden Administration Considers New China Export Ban: Report</a>
Todaro assumed a $15/TH sale price throughout 2025 at a production cost of $11/TH, which is in line with peers Canaan Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>). This added $47 million in EBITDA (partly offset by declines in the hosting business).
The analyst is increasingly excited about Bitdeer&#8217;s manufacturing segment, given customs-related issues with competitor Bitmain and the new machine architecture that Bitdeer is pioneering, which could lead to the most efficient ASICs on the market in the second half of 2025.
He noted that Bitdeer is a high-quality, underappreciated Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) miner. The company presents an attractive, diversified revenue base that will perform well in bitcoin bull and bear market cycles. This diversified model also provides a buffer to prop mining during the bitcoin halving event, which results in block rewards industry-wide declining by 50%.
Additionally, Bitdeer ranks in the middle- lower end of public bitcoin miners regarding production costs, offering an attractive gross margin with bitcoin at prices above $50-60k.
Lastly, Todaro noted the stock will re-rate to a higher multiple, more in line with peers based on hash rate expansion in 2025 (fueled by its recent production of new generation mining machines, which Bitdeer sources at &#8220;production cost&#8221;) and its growing presence in U.S. capital markets.
Todaro projected fourth-quarter revenue of $71.0 million and EPS loss of $0.17.
Price Action: BTDR stock is down 8.43% at $16.94 at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42896233/japanese-chipmaker-rapidus-sets-sights-on-broadcom-to-emulate-taiwan-semiconductors-market-dominance" target="_blank" rel="noreferrer noopener">Japanese Chipmaker Rapidus Sets Sight on Broadcom to Emulate Taiwan Semiconductor&#8217;s Market Dominance</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Reiteration

Trading Ideas

$BTC

BTDR

Bitdeer Growth Fueled By Strong Machine Sales, Efficient ASICs, Diversified Revenue, And High-Performance Computing Potential: Analyst

On Monday, Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock skyrocketed with a strong session volume of 201.04 million, compared to the average volume of 362.72k, according to data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
Phio reported pathologic responses for patients enrolled in the 2nd cohort, which includes two patients with a complete response <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/42942185/phio-pharmaceuticals-announces-promising-results-of-second-cohort-from-its-ongoing-clinical-study-o" rel="noreferrer noopener">or 100% tumor clearance</a>.
Phio&#8217;s ongoing Phase 1b clinical study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2 and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma.
Of the patients enrolled to date, six patients were diagnosed with cutaneous squamous cell carcinoma, and one patient was diagnosed with metastatic melanoma.
At Day 36 (tumor excision), while patients in the first cohort had stable disease, results are now available for the four patients who completed treatment in the 2nd&nbsp;cohort:
<ul>
<li>Complete response (100% tumor clearance) is reported for 2 patients with cutaneous squamous cell carcinoma.</li>
<li>Partial response (90% tumor clearance) is reported for one patient with cutaneous squamous cell carcinoma and one with stable disease, having not progressed.</li>
</ul>
No dose-limiting toxicities or clinically relevant treatment-emergent adverse events have occurred in the patients receiving intratumoral PH-762, and the intratumoral injections have been well tolerated.
Preclinical <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38363607/why-is-penny-stock-phio-pharmaceuticals-trading-higher-on-monday" rel="noreferrer noopener">studies demonstrated</a>:
<ul>
<li>PH-762 is rapidly taken up by cells and robustly silences PD-1 mRNA and protein in lymphocytes within the tumor microenvironment (TME).</li>
<li>Intratumoral injection of murine PH-762 (mPH-762) significantly inhibits tumor growth in murine tumor models and is well-tolerated.</li>
<li>mPH-762-mediated silencing of PH-762 within the TME may generate memory-specific T cells, promoting IFN-γ release in the TME</li>
<li>Studies in non-human primates demonstrate that PH-762 is well-tolerated and does not induce the release of cytokines associated with cytokine release syndrome.</li>
</ul>
Price Action: PHIO stock is up 378.7% at $8.09 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal" target="_blank" rel="noreferrer noopener">Like Bristol-Myers Squibb And AbbVie, Johnson &amp; Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal</a></li>
</ul>

Biotech

Health Care

Movers

General

PHIO

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

SEMR

SEMrush shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $17 to $20.

Lithia Motors's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) short percent of float has fallen 14.76% since its last report. The company recently reported that it has 1.98 million shares sold short, which is 8.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lithia Motors Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736790321_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lithia Motors has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Lithia Motors's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lithia Motors's peer group average for short interest as a percentage of float is 9.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Lithia Motors's Recent Short Interest

Simon Property Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) short percent of float has fallen 7.02% since its last report. The company recently reported that it has 4.83 million shares sold short, which is 2.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Simon Property Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736790316_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Simon Property Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Simon Property Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Simon Property Group's peer group average for short interest as a percentage of float is 6.30%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Simon Property Group?

Amgen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NYSE">AMGN</a>) short percent of float has fallen 3.26% since its last report. The company recently reported that it has 11.17 million shares sold short, which is 2.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Amgen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736790311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Amgen has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Amgen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Amgen's peer group average for short interest as a percentage of float is 5.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

AMGN

Peering Into Amgen's Recent Short Interest

Citigroup analyst Andrew Kaplowitz maintains Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) with a Buy and lowers the price target from $119 to $115.

Citigroup Maintains Buy on Ingersoll Rand, Lowers Price Target to $115

NextEra Energy shares are trading lower after BMO Capital downgraded the stock from Outperform to Market Perform and cut its price target from $26 to $18.

<a href="https://www.bloomberg.com/news/articles/2025-01-13/eu-considers-expanding-probe-into-musk-s-x-digital-chief-says?utm_source=google&amp;utm_medium=bd&amp;cmpId=google">https://www.bloomberg.com/news/articles/2025-01-13/eu-considers-expanding-probe-into-musk-s-x-digital-chief-says?utm_source=google&amp;utm_medium=bd&amp;cmpId=google</a>
&nbsp;
The European Union is considering expanding its investigation into whether Elon Musk's X social network breached its content moderation rulebook, the bloc's top digital official said.

Macro Economic Events

Legal

Global

Economics

'EU Considers Expanding Probe Into Musk's X, Digital Chief Says' - Bloomberg News

Morgan Stanley analyst Brian Nowak maintains Yelp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) with a Underweight and raises the price target from $34 to $35.

YELP

Morgan Stanley Maintains Underweight on Yelp, Raises Price Target to $35

ADMA

ADMA Biologics shares are trading lower. The company reported preliminary FY24 revenue results.

Citigroup analyst Andrew Kaplowitz maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Neutral and lowers the price target from $279 to $265.

Citigroup Maintains Neutral on Illinois Tool Works, Lowers Price Target to $265

M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) will release earnings results for its fourth quarter, before the <a href="https://www.benzinga.com/quote/MTB/earnings">opening bell on Thursday, Jan. 16, 2025.</a>
Analysts expect the Buffalo, New York-based company to report quarterly earnings at $3.74 per share, up from $3.60 per share in the year-ago period. M&amp;T Bank projects to report revenue of $2.34 billion for the recent quarter, compared to $2.3 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 6, M&amp;T Bank named Krista Phillips as Chief Customer Officer.
M&amp;T Bank shares fell 1.8% to close at $187.75 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/MTB/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Truist Securities analyst Brian Foran initiated coverage on the stock with a Buy rating and a price target of $233 on Jan. 7, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Compass Point analyst David Rochester maintained a Neutral rating and boosted the price target from $220 to $250 on Dec. 10, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Keefe, Bruyette &amp; Woods analyst David Konrad maintained a Market Perform rating and raised the price target from $205 to $221 on Dec. 4, 2024. This analyst has an accuracy rate of 73%.</li>
<li>JP Morgan analyst Steven Alexopoulos downgraded the stock from Overweight to Neutral and raised the price target from $215 to $223.5 on Dec. 4, 2024. This analyst has an accuracy rate of 72%.</li>
<li>Piper Sandler analyst Frank Schiraldi maintained an Overweight rating and boosted the price target from $205 to $243 on Nov. 27, 2024. This analyst has an accuracy rate of 77%.</li>
</ul>
Considering buying MTB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13062616/image-68-1024x592.png" alt="" class="wp-image-730254" style="width:659px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13062616/image-68-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13062616/image-68-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13062616/image-68-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13062616/image-68.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42923396/wall-streets-most-accurate-analysts-weigh-in-on-3-real-estate-stocks-with-over-7-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields</a></li>
</ul>

Earnings

Markets

M&T Bank Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Morgan Stanley analyst Neel Kumar maintains Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) with a Equal-Weight and lowers the price target from $155 to $130.

Morgan Stanley Maintains Equal-Weight on Westlake, Lowers Price Target to $130

AKBA

Akebia Therapeutics shares are trading higher after the company announced near 100% U.S. dialysis coverage for Vafseo with a Phase 3 trial for late-stage non-dialysis CKD patients planned for mid-2025.

Citigroup analyst Vladimir Bystricky maintains IDEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>) with a Buy and lowers the price target from $269 to $267.

Comments

Okamura

Okamura (OKAMF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga